Skip to search formSkip to main contentSkip to account menu

PNU 157706

Known as: PNU-157706 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Androstenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Combined treatment of Dunning R3327 rat prostatic tumor with the 5α-reductase inhibitor PNU 157706 and the antiandrogen bicalutamide
Abstract PNU 157706 [N-(1,1,1,3,3,3-hexafluorophenyl- propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide], a novel, potent and… 
1999
1999
Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
The steroid 5 alpha-reductase enzyme catalyzes the conversion of testosterone to the potent androgen 5 alpha-dihydrotestosterone… 
1998
1998
PNU 157706, a novel dual type I and II 5alpha-reductase inhibitor.
PNU 157706 is a novel dual inhibitor of 5alpha-reductase (5alpha-R), the enzyme responsible for the conversion of testosterone (T… 
1998
1998
Effect of the dual 5α-reductase inhibitor Pnu 157706 on the growth of dunning R3327 prostatic carcinoma in the rat
1998
1998
Effect of the dual 5alpha-reductase inhibitor PNU 157706 on the growth of dunning R3327 prostatic carcinoma in the rat.
PNU 157706 [N-(1,1,1,3,3,3-hexafluorophenylpropyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide] is a novel, potent and… 
1998
1998
Determination of PNU 157706, a new dual inhibitor of 5alpha-reductase, in rat plasma by high-performance liquid chromatography with ultraviolet detection.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)